The reproductive "master switch" — with real modern clinical science and three great backstories. This is one of the register's stronger entries: a genuine upstream controller of human reproduction, backed by actual randomized trials (Imperial College London), yet still research-only. Three threads of intrigue: (1) it's named after Hershey's Kisses chocolate; (2) it was discovered in cancer research (as a metastasis suppressor) before anyone knew it ran reproduction; (3) recent placebo-controlled trials show it modulates the "attraction" and desire circuits of the brain — a real, published sexual-desire signal, not gray-market folklore.
Kisspeptin-10 is the minimal active fragment of kisspeptin — the hypothalamic peptide that sits at the top of the reproductive hormone axis and acts as its master switch. It works upstream: activating KISS1R on GnRH neurons, which drives pulsatile GnRH → LH/FSH → testosterone/estradiol. Its story is unusually rich: the gene was named after Hershey's Kisses chocolate, was discovered in cancer research (as the metastasis suppressor "metastin") before its reproductive role was known, and proved essential when people lacking it were found not to undergo puberty. Crucially — and unlike most compounds here — kisspeptin has real, current clinical science behind it: Imperial College London teams have run trials in hypogonadism, IVF triggering, hypothalamic amenorrhea, and hypoactive sexual desire disorder, where randomized placebo-controlled studies showed it modulates the brain's arousal/"attraction" circuits and reduces sexual aversion. The honest caveats: it's still research-only (not approved), its strongest data are in specific clinical settings (not the bodybuilding "testosterone restart" use it's often sold for), and it has a very short half-life. Bottom line: a genuinely important hormone with real translational momentum — promising and well-studied, but not yet an approved therapy.
research use only; not approved by FDA or EMA for any therapeutic use. But — unlike most gray-market peptides — it has an active, legitimate clinical-trial pipeline (Phase 1/2), so its "unproven" status is "not yet approved, actively being developed," not "fringe."
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Kisspeptin-10 (KP-10) changes - nothing else.
Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.
via PubChem exact-name match (Kisspeptin-10) · high confidence
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.